Journal article
Additional Events in the RE-LY Trial
Abstract
To the Editor: Boehringer Ingelheim recently conducted a targeted review of the 1387 deaths that occurred during the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial,1 which...
Authors
Connolly SJ; Wallentin L; Yusuf S
Journal
The New England Journal of Medicine, Vol. 371, No. 15, pp. 1464–1465
Publisher
Massachusetts Medical Society
Publication Date
October 9, 2014
DOI
10.1056/nejmc1407908
ISSN
0028-4793